Table 1.
Characteristics of the study population (1999-2018)
| Patients | Study population (all diagnosed PLHIV) |
People who initiated ART | |||
|---|---|---|---|---|---|
| 24,569 | (100%) | 22,120 | (100%) | ||
| Observation time | Total PY | 171,990 | 164,691 | ||
| Sex | Male | 19,794 | (81%) | 17,794 | (80%) |
| Female | 4775 | (19%) | 4326 | (20%) | |
| HIV transmission risk | Men who have sex with men (MSM) | 13,006 | (53%) | 11,676 | (53%) |
| Heterosexual contacts | 3227 | (13%) | 2954 | (13%) | |
| High prevalence country | 3200 | (13%) | 2958 | (13%) | |
| People with injecting drug use | 1612 | (7%) | 1411 | (6%) | |
| Other | 212 | (1%) | 203 | (1%) | |
| Unknown | 3312 | (13%) | 2918 | (13%) | |
| Region of origin | Germany | 16,683 | (68%) | 15,065 | (68%) |
| Eastern Europe | 682 | (3%) | 592 | (3%) | |
| Central Europe | 1129 | (5%) | 1021 | (5%) | |
|
Western Europe (excl. Germany) |
949 | (4%) | 834 | (4%) | |
| Africa | 2998 | (12%) | 2749 | (12%) | |
| Asia | 686 | (3%) | 649 | (3%) | |
| America | 546 | (2%) | 491 | (2%) | |
| Caribbean/Ozeania | 107 | (0%) | 96 | (0%) | |
| Unknown | 789 | (3%) | 623 | (3%) | |
| Age at Enrolment (years) | Median (IQR) | 37 | (30-45) | 37 | (31-45) |
| Enrollment | 1999–2001 | 3422 | (14%) | 3098 | (14%) |
| 2002–2005 | 5454 | (22%) | 4834 | (22%) | |
| 2006–2009 | 5529 | (23%) | 4925 | (22%) | |
| 2010–2013 | 5343 | (22%) | 4819 | (22%) | |
| 2014–2018 | 4821 | (20%) | 4444 | (20%) | |
| Observation time (years) | Median (IQR) | 5.9 | (2.4-11) | 6.5 | (2.8-11.5) |
| Number of viral loads | Median (IQR) | 18 | (7-35) | 17 | (8-32) |
| Distance between viral loads (days) | Median (IQR) | 91 | (64–112) | 91 | (70–112) |
|
Viral load baseline (copies/ml) |
Median (IQR) | 49,973 | (9350–198,000) | 55,544 | (10,899–211,000) |
|
CD4 cell count baseline (cells/μl) |
Median (IQR) | 349 | (174–537) | 328 | (157–513) |
| Initiated ART | N (%) | 22,120 | (90%) | ||
| ART start period | 1999–2001 | 2416 | (11%) | ||
| 2002–2005 | 3948 | (18%) | |||
| 2006–2009 | 4833 | (22%) | |||
| 2010–2013 | 5636 | (25%) | |||
| 2014–2018 | 5287 | (24%) | |||
| not started ART | 2449 | (11%) | |||
| Age at ART start (years) | Median (IQR) | 39 | (32-46) | ||
| Time between enrollment and ART (days) | Mean (IQR) | 321 | (0–237) | ||
|
Viral load ART start (copies/ml) |
Median (IQR) | 62,000 | (12,300-212,604) | ||
|
CD4 cell count ART start (cells/μl) |
Median (IQR) | 271 | (133–429) | ||
| ART duration (years) | Median (IQR) | 5.5 | (2.3-9.9) | ||